Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897543 · ClinicalTrials.gov registry record · Phase 1
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
A Phase 1 study of Carcinoma, Hepatocellular, sponsored by Abivax S.A..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 2
- Study locations
NCT03897543: Recruiting Phase 1 study of Carcinoma, Hepatocellular, sponsored by Abivax S.A..
NCT03897543 is a Phase 1 study of Carcinoma, Hepatocellular that is actively recruiting participants, run by Abivax S.A.. The registered enrollment target is 48 participants, below the 611-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03897543, a Phase 1 study of Carcinoma, Hepatocellular, is actively recruiting participants, sponsored by Abivax S.A..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 2
- Study locations
Study Summary
Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma
Primary Outcome
Adverse Events evaluated according to CTC-AE
Conditions Studied
Interventions
- DRUG ABX196
Study Locations (2)
California
- Scripps Clinic Torrey Pines - La Jolla
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-08-30 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 1 |
What NCT03897543 shows while recruiting
NCT03897543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 611-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 1 intervention - of which ABX196 is the first listed.
NCT03897543 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT03897543 about?
NCT03897543 is a clinical study titled "ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma". Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma
What is the current status of trial NCT03897543?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2019-08-30. Estimated completion is 2023-06-30.
What conditions does trial NCT03897543 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular.
What interventions are being tested in trial NCT03897543?
The interventions under investigation include: ABX196 (DRUG).
Who is sponsoring clinical trial NCT03897543?
This trial is sponsored by Abivax S.A., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03897543 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03897543's enrollment target sits among peer trials
48 20th of 27 higher than 7 of 27 other Carcinoma, Hepatocellular trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Hepatocellular trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
COMPLETED · Phase 1
-
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
COMPLETED · Phase 1
-
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
COMPLETED · Phase 1
-
Sorafenib and TRC105 in Hepatocellular Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI